Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 121-126

  Blaszkowsky, L S ^a   Ryan, D P ^a   Szymonifka, J ^a   Borger, D R ^a   Zhu, A X ^a   Clark, J W ^a   Kwak, E L ^a   Mamon, H J ^a   Allen, J N ^a   Vasudev, E ^a   Shellito, P C ^b   Cusack, J C ^b   Berger, D L ^b   Hong, T S ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bevacizumab; Erlotinib; Radiation; Rectal cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; ERLOTINIB; FLUOROURACIL;

ABDOMINAL INFECTION; ACNE; ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COLITIS; COLON ANASTOMOSIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; ORAL MUCOSITIS; OUTCOME ASSESSMENT; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RADIATION DERMATITIS; RASH; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER; RECTUM PAIN; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SURVIVAL RATE; SURVIVAL TIME; URINARY TRACT OBSTRUCTION; URINE RETENTION; WOUND INFECTION;

BEVACIZUMAB; ERLOTINIB; RADIATION; RECTAL CANCER;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; NEOADJUVANT THERAPY; QUINAZOLINES; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84903815748     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt516     Document Type: Article

References (29)

1. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
2. Rodel C, Martus P, Papadoupolos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-8696.
3. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
4. Van Cutsem E, Tabernero J, Lakorny R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen. J Clin Oncol 2012; 30: 3499-3506.
5. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
6. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
7. Willett CG, Duda DG, di Tomaso E et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020-3026.
8. Czito BG, Bendell JC, Willett CG et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 2007; 68: 472-478.
9. Crane CH, Eng C, Feig BW et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76: 824-830.
10. Debucquoy A, Haustermans K, Daemen A et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009; 27; 2751-2757.
11. Bengala C, Bettelli S, Bertolini F et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 2009; 20: 469-474.
12. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M et al. Multideterminants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009; 4: e7287. doi: 10.1371/journal. pone.
13. Colakoglu T, Yildirim D, Kayaselcuk F et al. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence? Am J Surg 2008; 195: 719-725.
14. Hofheinz RD, Horisberger K, Woernle C et al. Phase I trial of cetuximab with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66: 1384-1390.
15. Rodel C, Liersch T, Hermann RM et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007; 25: 110-117.
16. Bozec A, Formento P, Lassalle S et al. Dual inhibition of the EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer 2007; 97: 65-72.
17. Yoo DS, Kirkpatrick JP, Craciunescu O et al. Prospective trial of synchronous bevacizumab, erlotinib and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res 2012; 18: 1404-1414.
18. Socinski MA, Stinchcombe TE, Moore DT et al. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small lung cancer: results of a phase I/II trial. J Clin Oncol 2012; 30: 3953-3959.
19. Bendell JC, Meluch A, Peyton J et al. A phase II trial of preoperative concurrent chemotherapy/radiation plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clin Adv Hematol Oncol 2012; 10: 430-437.
20. Dias-Santagata D, Akhavanfard S, David SS et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010; 2: 146-158.
21. Roh MS, Colangelo LH, O'Connell MJ et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R- J Clin Oncol 2009; 27: 5124-5130.
22. Aschele C, CIonini L, Lonardi S et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29: 2773-2780.
23. Gerard JP, Azria D, Gourgou-Bourgade S et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige2. J Clin Oncol 2010; 28: 1638-1644.
24. Kennecke H, Berry S, Wong R et al. Preoperative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer. Eur J Cancer 2012; 48: 37-45.
25. Valentini V, De Paoli A, Gambacorta MA et al. Infusional 5-fluorouracil and ZD1839 (Gefininib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL/0092). Int J Radiat Oncol Biol Phys 2008; 72: 644-649.
26. Czito BG, Willett CG, Bendal JC et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 2006; 24: 656-662.
27. Van Triest B, Kuenen B, Ghotra V et al. Feasibility study of erlotinib plus radiotherapy in patients with locally advanced or recurrent rectal carcinoma. Int J Radiat Oncol Biol Phys. 2008; 72: 69s (suppl: abstr 153).
28. Tournigand C, Samson B, Sheithauer W et al. Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): efficacy and safety result so of the international GERCOR DREAM phase III trial. J Clin Oncol 2012; 30 (suppl;abstr LBA3500).
29. Roh MS, Yothers GA, O'Connell MJ et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011; 29 (suppl;abstr 3503).